WeTrials
Active, not recruiting

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors

What is this study?

This study is testing a new experimental drug called LP-184 to see if it is safe and effective for people with advanced cancers that have not responded to standard treatments. It aims to find the right dosage for patients and see if the drug can help shrink or control tumors.

Who can participate?

This trial is for adults (18+) with advanced solid tumors, such as specific types of breast, lung, or brain cancer, who have exhausted other treatment options. You must be physically active enough to carry out daily tasks and have tumors that doctors can clearly measure on scans.

What will happen?

Participants will receive the drug through an IV infusion on days 1 and 8 of every 21-day cycle. Throughout the study, the medical team will monitor you closely to ensure the treatment is safe and to track how your body responds to the medicine.

Where and when?

The study is currently active but is not accepting new patients at this time. It is being conducted at medical centers in Springdale, Arkansas; Indianapolis, Indiana; and Louisville, Kentucky.

Key Points
  • 1The study tests an experimental cancer drug to determine its safety and appropriate dosage.
  • 2Patients receive treatment in 21-day cycles with regular health check-ups.
  • 3This trial is for patients who have already tried standard treatments or have limited options remaining.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid TumorMetastatic Solid TumorGBMTNBC - Triple-Negative Breast CancerNSCLCPancreatic AdenocarcinomaDDR Gene Mutation

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.